Track topics on Twitter Track topics that are important to you
SAN FRANCISCO and LONDON, Nov. 10, 2015 /PRNewswire/ -- On Saturday, Nov. 7, GSK announced results from the BLISS-SC Phase III pivotal study in patients with active, autoantibody-positive systemic lup...
(MedPage Today) -- And almost a third of patients developing RA had the erosive form
(MedPage Today) -- Two autoimmune diseases share clinical and serological features
Dr Fox reports on the 13th International Symposium on Sjogren's Syndrome and shares his perspective on advances in the field. Medscape Rheumatology
A retrospective review of patients with Sjogren syndrome underlines the need for ophthalmologists to screen for this disorder as soon as its tell-tale signs present. Medscape Ophthalmology
GlaxoSmithKline's Benlysta, or belimumab, combined with standard of care, met the primary and secondary endpoints of a late-s -More-
Belimumab is an approved therapy for the treatment of systemic lupus erythematosus (SLE). This study examined the real-world utilization patterns of belimumab and standard SLE therapies in patients af...
Belimumab (Benlysta(®)) is a fully humanized monoclonal antibody that inhibits B-lymphocyte stimulator (also known as B cell activating factor of the tumor necrosis factor family) and was approved by...
To estimate the cost-effectiveness of belimumab in patients with systemic lupus erythematosus (SLE) presenting positive biomarkers and active disease despite standard treatment (ST), from the Spanish ...
The purpose of this analysis is to evaluate the cost-effectiveness of belimumab, a new biological treatment specifically developed for the treatment of Systemic Lupus Erythematosus (SLE), in the Itali...